{"seq": 1, "variant": "control", "cmd": "pm quick metabolic tumor volume prognostic PSMA PET prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41703276\", \"title\": \"Distinct prognostic value of [18F]FDG PET and [68Ga]Ga-PSMA-11 PET in advanced hormone-sensitive prostate cancer.\", \"authors\": [\"Li Ang\", \"Wu Haotian\", \"Zhou Xiang\", \"Zhu Yinjie\", \"Zhang Weiwei\", \"Shen Kai\", \"Tang Linglin\", \"Yi Jiayan\", \"Liu Bo\", \"Su Ruopeng\", \"Liu Xinyu\", \"Chai Xinyu\", \"Wang Qi\", \"Pan Jiahua\", \"Xue Wei\"], \"journal\": \"Communications medicine\", \"year\": \"2026\", \"date\": \"2026-02-17\", \"abstract\": \"This study aimed to evaluate the distinct prognostic value of [18F]FDG and [68Ga]Ga-PSMA-11 PET imaging in advanced hormone-sensitive prostate cancer, highlighting their complementary roles at both patient and lesion levels. This study retrospectively included 298 patients with newly diagnosed prostate cancer who underwent baseline dual-tracer PET imaging. Quantitative PET parameters for both [18F]FDG and [68Ga]Ga-PSMA-11 were extracted. Clinical outcomes, including progression-free survival, biochemical response, and radiographic response, were collected during follow-up. Lesion-based analysis was performed in 267 measurable lesions to evaluate the association between tracer uptake and local radiographic response, as determined by changes in lesion diameter following systemic therapy. Here we show that higher whole-body [18F]FDG uptake, including total lesion glycolysis (HR\u2009=\u20093.525, p\u2009<\u20090.001) and metabolic tumor volume (HR\u2009=\u20092.757, p\u2009<\u20090.001), is significantly associated with shorter progression-free survival. In contrast, only PSMA-derived tumor volume (HR\u2009=\u20092.019, p\u2009=\u20090.018), but not total lesion PSMA uptake (HR\u2009=\u20091.438, p\u2009=\u20090.221), demonstrates prognostic value. Moreover, patients with higher whole-body [18F]FDG burden receive greater benefit from chemotherapy (HR\u2009=\u20092.936, p\u2009=\u20090.004). At the lesion level, higher [68Ga]Ga-PSMA-11 uptake is significantly correlated with more favorable radiographic response (p\u2009<\u20090.001), while lesion-level [18F]FDG uptake does not demonstrate predictive value. [18F]FDG PET and [68Ga]Ga-PSMA-11 PET provide distinct but complementary prognostic", "stderr": "", "elapsed_s": 1.983, "ts": 1771589789.6450229}
{"seq": 2, "variant": "control", "cmd": "pm search metabolic tumor volume prognostic factor PSMA PET prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41486328\n41421031\n41363980\n41287510\n41281171\n41067860\n41021003\n40851054\n40696478\n40665782\n40647625\n40551434\n40517368\n40397137\n40278858\n40259392\n40137954\n40113645\n40001235\n39939019\n39847077\n39794510\n39477497\n39442347\n39313655\n39110196\n39089299\n39080696\n38948055\n38835183\n38835182\n38752520\n38726601\n38693454\n38563882\n37770114\n37147881\n36261050\n35902300\n35045552\n34933889\n34902034\n34772793\n34729965\n34395251\n34373733\n33958536\n33866336\n33783752\n33754047\n33586097\n33560717\n33059819\n32948911\n32928177\n32762625\n32716402\n32685010\n31780798\n31724145\n31338731\n31214958\n29748236\n29725716\n29454548\n29181556\n28941866\n27229485\n", "stderr": "", "elapsed_s": 1.166, "ts": 1771589914.6169333}
{"seq": 3, "variant": "control", "cmd": "pm search metabolic tumor volume prognostic factor PSMA PET prostate cancer --max 100", "exit_code": 0, "stdin_lines": 0, "stdout": "41486328\n41421031\n41363980\n41287510\n41281171\n41067860\n41021003\n40851054\n40696478\n40665782\n40647625\n40551434\n40517368\n40397137\n40278858\n40259392\n40137954\n40113645\n40001235\n39939019\n39847077\n39794510\n39477497\n39442347\n39313655\n39110196\n39089299\n39080696\n38948055\n38835183\n38835182\n38752520\n38726601\n38693454\n38563882\n37770114\n37147881\n36261050\n35902300\n35045552\n34933889\n34902034\n34772793\n34729965\n34395251\n34373733\n33958536\n33866336\n33783752\n33754047\n33586097\n33560717\n33059819\n32948911\n32928177\n32762625\n32716402\n32685010\n31780798\n31724145\n31338731\n31214958\n29748236\n29725716\n29454548\n29181556\n28941866\n27229485\n", "stderr": "", "elapsed_s": 0.988, "ts": 1771589926.2519896}
{"seq": 4, "variant": "control", "cmd": "pm fetch", "exit_code": 0, "stdin_lines": 68, "stdout": "<?xml version=\"1.0\" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC \"-//NLM//DTD PubMedArticle, 1st January 2025//EN\" \"https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd\">\n<PubmedArticleSet>\n<PubmedArticle><MedlineCitation Status=\"MEDLINE\" Owner=\"NLM\" IndexingMethod=\"Automated\"><PMID Version=\"1\">41486328</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>31</Day></DateRevised><Article PubModel=\"Print-Electronic\"><Journal><ISSN IssnType=\"Electronic\">1867-108X</ISSN><JournalIssue CitedMedium=\"Internet\"><Volume>44</Volume><Issue>2</Issue><PubDate><Year>2026</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Japanese journal of radiology</Title><ISOAbbreviation>Jpn J Radiol</ISOAbbreviation></Journal><ArticleTitle><sup>18</sup>F-PSMA-1007 PET/CT tumor volume quantification: a game-changing prognostic biomarker for first-line ARPI therapy in metastatic castration-resistant prostate cancer.</ArticleTitle><Pagination><StartPage>383</StartPage><EndPage>393</EndPage><MedlinePgn>383-393</MedlinePgn></Pagination><ELocationID EIdType=\"doi\" ValidYN=\"Y\">10.1007/s11604-025-01920-4</ELocationID><Abstract><AbstractText Label=\"PURPOSE\" NlmCategory=\"OBJECTIVE\">This study evaluates the prognostic value of baseline <sup>18</sup>F-PSMA-1007 PET/CT-derived volumetric metabolic parameters in metastatic castration-resistant prostate cancer (mCRPC) patients initiating first-line androgen receptor pathway inhibitor (ARPI) therapy, while exploring their relationship with serum PSA and developing a risk stratification model.</AbstractText><AbstractText Label=\"RESULTS\" NlmCategory=\"RESULTS\">Both wbPSMA-TV (r&#x2009;=&#x2009;0.70) and wbTL-PSMA (r&#x2009;=&#x2009;0.67) correlated with baseline PSA. Multivariable analysis identified bone metastasis count (adjusted OR [aOR] 0.19, 95% CI 0.11-0.35; P&#x2009;&lt;&#x2009;0.001) and wbPSMA-TV (aOR&#x2009;=&#x2009;0.77, 95% CI 0.65-0.91; P&#x2009;&lt;&#x2009;0.001) as independent predictors of early PSA response. Ba", "stderr": "", "elapsed_s": 1.113, "ts": 1771589927.3737144}
